A major challenge in myocardial infarction (MI)-related heart failure treatment using microRNA is the efficient and sustainable delivery of miRNAs into myocardium to achieve functional improvement through stimulation of intrinsic myocardial restoration. In this study, we established an in vivo delivery system using polymeric nanoparticles to carry miRNA (miNPs) for localized delivery within a shear-thinning injectable hydrogel. The miNPs triggered proliferation of human embryonic stem cell-derived cardiomyocytes and endothelial cells (hESC-CMs and hESC-ECs) and promoted angiogenesis in hypoxic conditions, showing significantly lower cytotoxicity than Lipofectamine. Furthermore, one injected dose of hydrogel/miNP in MI rats demonstrated significantly improved cardiac functions: increased ejection fraction from 45% to 64%, reduced scar size from 20% to 10%, and doubled capillary density in the border zone compared to the control group at 4 weeks. As such, our results indicate that this injectable hydrogel/miNP composite can deliver miRNA to restore injured myocardium efficiently and safely.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2019) studied Myocardial infarction. Injectable shear-thinning hydrogel with polymeric nanoparticles carrying miRNA (hydrogel/miNP) vs. Control group (and Lipofectamine for in vitro cytotoxicity) was evaluated on Ejection fraction, scar size, and border zone capillary density at 4 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: